Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 22

1.

Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?

Coast J, Smith R, Karcher AM, Wilton P, Millar M.

Health Econ. 2002 Oct;11(7):637-47.

PMID:
12369064
2.

National intelligence estimate: the global infectious disease threat and its implications for the United States.

United States. National Intelligence Council.

Environ Change Secur Proj Rep. 2000 Summer;(6):33-65.

PMID:
12296202
3.

On the implications of endogenous resistance to medications.

Laxminarayan R, Weitzman ML.

J Health Econ. 2002 Jul;21(4):709-18.

PMID:
12146599
4.

Antimicrobial resistance: a global response.

Smith RD, Coast J.

Bull World Health Organ. 2002;80(2):126-33.

5.

Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness.

Wilton P, Smith R, Coast J, Millar M.

J Health Serv Res Policy. 2002 Apr;7(2):111-7. Review.

PMID:
11934376
6.

Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa.

Wilton P, Smith RD, Coast J, Millar M, Karcher A.

Int J Tuberc Lung Dis. 2001 Dec;5(12):1137-42.

PMID:
11769772
7.

Antimicrobial resistance: the importance of developing long-term policy.

Smith RD.

Bull World Health Organ. 1999;77(10):862. No abstract available.

8.

The antibacterial paradox: essential drugs, effectiveness, and cost.

Fasehun F.

Bull World Health Organ. 1999;77(3):211-6.

9.

Controlling antimicrobial resistance: a proposed transferable permit market.

Smith RD, Coast J.

Health Policy. 1998 Mar;43(3):219-32.

PMID:
10178572
10.

An economic perspective on policy to reduce antimicrobial resistance.

Coast J, Smith RD, Millar MR.

Soc Sci Med. 1998 Jan;46(1):29-38. Review.

PMID:
9464666
11.

Biological weapons control. Prospects and implications for the future.

Kadlec RP, Zelicoff AP, Vrtis AM.

JAMA. 1997 Aug 6;278(5):351-6.

PMID:
9244311
12.

Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital.

John JF Jr, Fishman NO.

Clin Infect Dis. 1997 Mar;24(3):471-85. Review.

PMID:
9114203
13.

Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?

Coast J, Smith RD, Millar MR.

Health Econ. 1996 May-Jun;5(3):217-26. Review.

PMID:
8817296
14.

Over-the-counter antimicrobials: the hidden costs of resistance.

Smith RD, Coast J, Millar MR.

J Antimicrob Chemother. 1996 May;37(5):1031-2. No abstract available.

PMID:
8737155
15.

Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.

Tomasz A.

N Engl J Med. 1994 Apr 28;330(17):1247-51. No abstract available.

16.

Can antibiotic resistance be controlled?

Murray BE.

N Engl J Med. 1994 Apr 28;330(17):1229-30. No abstract available.

PMID:
8139634
17.

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

McCaig LF, Hughes JM.

JAMA. 1995 Jan 18;273(3):214-9. Erratum in: JAMA 1998 Feb 11;279(6):434.

PMID:
7807660
18.

A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16)

Cox RA, Conquest C, Mallaghan C, Marples RR.

J Hosp Infect. 1995 Feb;29(2):87-106.

PMID:
7759837
19.

The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial.

Foxman B, Valdez RB, Lohr KN, Goldberg GA, Newhouse JP, Brook RH.

J Chronic Dis. 1987;40(5):429-37.

20.

Bug/drug resistance. Sometimes less is more.

Phelps CE.

Med Care. 1989 Feb;27(2):194-203.

PMID:
2918766

Supplemental Content

Support Center